Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models

Journal of Lipid Research

Fabrizio Pin¹  David Massa²  Silvia Busquets³  Francisco J. López-Soriano⁴  Fabio Penna⁴  Josep M. Argilés⁴  Miriam Toledo⁵  Paola Costelli⁶ 

[1] Departament de Bioquímica i Biologia Molecular and Institut de Biomedicina (IBUB);Department of Clinical and Biological Sciences, University of Torino, Torino, Italy;Universitat de Barcelona, Barcelona, Spain;Departament de Bioquímica i Biologia Molecular and Institut de Biomedicina (IBUB);To whom correspondence should be addressed;Universitat de Barcelona, Barcelona, Spain;

关键词: anemia;    lipoprotein lipase;    lipogenesis;    lipolysis;   

DOI  :  

来源: DOAJ

【 摘 要 】

Cancer-associated cachexia is characterized, among other symptoms, by a dramatic loss of both muscle and fat. In addition, the cachectic syndrome is often associated with anemia. The object of the present investigation was to assess the effects of erythropoietin (EPO) treatment on experimental cancer cachexia models. The results clearly show that, in addition to the improvement of the hematocrit, EPO treatment promoted a partial preservation of adipose tissue while exerting negligible effects on muscle loss. Administration of EPO to tumor-bearing animals resulted in a significant increase of lipoprotein lipase (LPL) activity in adipose tissue, suggesting that the treatment favored triacylglycerol (TAG) accumulation in the adipose tissue. In vitro experiments using both adipose tissue slices and 3T3-L1 adipocytes suggests that EPO is able to increase the lipogenic rate through the activation of its specific receptor (EPOR). This metabolic pathway, in addition to TAG uptake by LPL, may contribute to the beneficial effects of EPO on fat preservation in cancer cachexia.

【 授权许可】

Unknown